Evidence map›Paper›PMID 40481006›Full record

ArticleScientific reports2025

Computational discovery of novel aryl hydrocarbon receptor modulators for psoriasis therapy.

Gianluca Santini, Laura Bonati, Stefano Motta

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Gianluca SantiniDepartment of Earth and Environmental Sciences, University of Milano-Bicocca, Milan, 20126, Italy.
Laura BonatiDepartment of Earth and Environmental Sciences, University of Milano-Bicocca, Milan, 20126, Italy. laura.bonati@unimib.it.
Stefano MottaDepartment of Earth and Environmental Sciences, University of Milano-Bicocca, Milan, 20126, Italy. stefano.motta@unimib.it.

Funding

National Psoriasis Foundation 1298983
6 · The paper itself

Abstract

The aryl hydrocarbon receptor (AhR) is a ligand-dependent transcription factor involved in the regulation of many pathophysiological processes. Among these, immune system modulation, as well as regulation of skin homeostasis and inflammation, make it a promising target for psoriasis therapy. Tapinarof, an AhR agonist recently approved for psoriasis treatment, exerts its action through antioxidant, anti-inflammatory and barrier-restoring effects. In this study, we employed a computational drug-discovery approach to identify novel AhR modulators with psoriasis therapeutic potential. We performed a multi-step similarity-based screening in PubChem. Molecular docking led to the identification of diverse chemical scaffolds with high docking scores and potential AhR activity, some belonging to chemical classes with known pharmacological relevance. The stability of the binding geometries of the most promising compounds of each family was then verified through molecular dynamics simulations and pharmacokinetic characteristics were predicted using ADMETlab 2.0 and SwissADME. Notably, several identified compounds suggest a possible interplay between AhR signaling and sirtuin modulation, highlighting a previously unexplored avenue in psoriasis therapy. Our findings underscore the potential of computational approaches in accelerating the discovery of novel AhR-targeting agents and provide a foundation for further experimental validation.

Indexed as

Drug DiscoveryPsoriasisReceptors, Aryl HydrocarbonBasic Helix-Loop-Helix ProteinsComputational BiologyHumansLigandsMolecular Docking SimulationMolecular Dynamics SimulationAHR protein, humanBasic Helix-Loop-Helix ProteinsLigandsReceptors, Aryl Hydrocarbon

Identifiers

PMID40481006
PMCPMC12144160

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.